N- (2- (4- (5H- dibenzo(a,d)cyclohepten- 5- yliden)piperidino)ethyl)- 1- formyl- 4- piperidinecarboxamide (AT 1015)

structure in first source

Also Known As:

AT 1015; (N-(2-(4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-piperidino)ethyl)-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate); AT-1015; N-(2-(4-(5H-dibenzo(a,d)cyclohepten-5-yliden)piperidino)ethyl)-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - Isonipecotic Acids: 1
      - N-(2-(4-(5H-dibenzo(a,d)cyclohepten-5-yliden)piperidino)ethyl)-1-formyl-4-piperidinecarboxamide: 4
- Heterocyclic Acids
  - Isonipecotic Acids: 1
    - N-(2-(4-(5H-dibenzo(a,d)cyclohepten-5-yliden)piperidino)ethyl)-1-formyl-4-piperidinecarboxamide: 4

Experts

1.	Hirose, K: 2 articles (12/2001 - 04/2000)
2.	Kihara, H: 2 articles (12/2001 - 04/2000)
3.	Koganei, H: 2 articles (12/2001 - 04/2000)
4.	Yamamoto, H: 2 articles (12/2001 - 04/2000)
5.	Yoshimoto, R: 2 articles (12/2001 - 04/2000)
6.	Hirose, Ken: 1 article (03/2004)
7.	Kihara, Hideaki: 1 article (03/2004)
8.	Komiyama, Takashi: 1 article (03/2004)
9.	Shigematsu, Hiroshi: 1 article (03/2004)
10.	Yoshimoto, Ryota: 1 article (03/2004)

Related Diseases

1.	Intermittent Claudication 02/01/2004 - "Randomized trial of AT-1015 for treatment of intermittent claudication. "
2.	Peripheral Vascular Diseases (Peripheral Vascular Disease) 04/01/2000 - "These results suggest that AT-1015 is a potent 5-HT2A receptor antagonist, and its insurmountable antagonism may be relevant to its therapeutic potential in peripheral vascular disease."
3.	Thrombosis (Thrombus) 12/21/2001 - "Pretreatment with AT-1015 (1 mg/kg, p.o.) significantly prolonged the time required to occlusion of the artery with thrombus, and the effect (3 mg/kg, p.o.) persisted for 24 h with significant inhibition of 5-HT-induced vascular contraction. " 12/21/2001 - "The antithrombotic activity of N-[2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidino)ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate (AT-1015; a 5-HT(2A) receptor antagonist) was studied in a photochemically induced arterial thrombosis (PIT) model in the rat femoral artery, and in the tail transection bleeding time test. " 12/21/2001 - "Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time."
4.	Ischemia 03/01/2004 - "AT-1015 was orally administered for 3 days after induction of ischemia. "

Related Drugs and Biologics

1.	5-HT2A Serotonin Receptor (5 HT2A Receptor)